Use of cannabinoids in treating chronic integumentary lesions
Keywords:
chronic wounds, refractory wounds, cannabinoids, TIME scheme.Abstract
Introduction: The skin fulfills important functions. When there are chronic injuries, morbidity and mortality increase and economic expense increase is generated. The use of cannabis derivatives has grown exponentially in recent years, due to their usefulness in the treatment of integumentary lesions.
Objective: To describe a series of cases of patients with refractory wounds treated with cannabis-based preparations and their evolution.
Methods: A study was carried out in three phases: First, the laboratory development of the product; second, the evaluation of possible adverse effects in healthy individual; and third, in 9 individuals with chronic wounds of different etiology, refractory to conventional treatments.
Results: Complete closure of wounds, which had been refractory to conventional treatments, was achieved, respecting the tissue, infection, moisture, edge scheme (TIME).
Conclusions: The topical cannabinoid improves the deregulation of keratinocytes at the edge of non-healing wounds, by inhibiting their hyperactive proliferation.
Downloads
References
1. Contreras Ruiz J. Abordaje y manejo de las heridas. 1 ed. INTERSISTEMAS; 2012.
2. Monroe L, Pepper L. Cannabinoides y enfermedades inflamatorias de la piel. BUENOS HUMOS. Una ofrenda musical a la Pachamama. 2017 [acceso 01/07/2022]. Disponible en: https://scholar.google.es/scholar?hl=es&as_sdt=0%2C5&q=piel+endocannabinoide&btnG
3. Pareja B. La piel y los sistemas transdérmicos. Folia dermatología Perú. 1996 [acceso 01/07/2022]:1-3. Disponible en: http://www.cidermperu.org/php/folia/pdf/f0038.pdf
4. Eagleston LRM, Kalani NK, Patel RR, Flaten HK, Dunnick CA, Dellavalle RP. Cannabinoids in dermatology: a scoping review. Dermatol Online J. 2018 Jun [acceso 01/07/2022];15;24(6). Disponible en: https://pubmed.ncbi.nlm.nih.gov/30142706/
5. Formukong EA, Evans AT, Evans FJ. The medicinal uses of cannabis and its constituents. Phytother Res. 1989 [acceso 01/07/2022];3(6):219-31. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1002/ptr.2650030602
6. Mechoulam R, Ben-Shabat S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. Nat ProdRep. 1999 [acceso 01/07/2022];16:131-43. Disponible en: https://pubmed.ncbi.nlm.nih.gov/10331283/
7. Evans FJ. The medicinal chemistry of cannabis: O’S-haughnessy’s legacy. PharmaceuticalSci. 1997 [acceso 01/07/2022];3:533-7. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.2042-7158.1997.tb00490.x
8. Gurley RJ, Aranow R, Katz M. Medicinal marijuana: a review. J Psychoactive Drugs. 1998 [acceso 01/07/2022];30(2):37-147. Disponible en: https://www.tandfonline.com/doi/abs/10.1080/02791072.1998.10399683
9. Hirst RA, Lambert DG, Notcutt WG. Pharmacology and potential therapeutic uses of cannabis. Br J Anaesth. 1998 [acceso 01/07/2022];81:77-84. Disponible en: https://pubmed.ncbi.nlm.nih.gov/9771275/
10. Pertwee RG. Cannabis and cannabinoids: pharmacology and rationale for clinical use. PharmaceuticalSci. 1997 [acceso 01/07/2022];3:539-45. Disponible en: https://pubmed.ncbi.nlm.nih.gov/10575283/
11. Ortonne JP, Clévy JP. (1994). Physiology of cutaneous cicatrization. La Revue du praticien. 2022 [acceso 01/07/2022];44(13):1733-7. Disponible en: https://europepmc.org/article/med/7939255
12. Wang LL, Zhao R, Li JY, Li SS, Liu M, Wang M, et al. Pharmacological activation of cannabinoid 2 receptor attenuates inflammation, fibrogenesis, and promotes re-epithelialization during skin wound healing. Eur J Pharmacol. 2016 [acceso 01/07/2022];786:128-36. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27268717/
13. Li SS, Wang LL, Liu M, Jiang SK, Zhang M, Tian ZL, et al. Cannabinoid CB(2) receptors are involved in the regulation of fibrogenesis during skin wound repair in mice. Mol Med Rep. 2016 [acceso 01/07/2022];13(4):3441-50. Disponible en: https://www.spandidos-publications.com/10.3892/mmr.2016.4961
14. Mounessa JS, Siegel JA, Dunnick CA, Dellavalle RP. The role of cannabinoids in dermatology. J Am AcadDermatol. 2017 Jul;77(1):188-90. DOI: https://doi.org/10.1016/j.jaad.2017.02.056
15. Dhadwal G, Kirchhof MG. The Risks and Benefits of Cannabis in the Dermatology Clinic. J Cutan Med Surg. 2018;22(2):194-9. DOI: https://doi.org/10.1177/1203475417738971
16. Morris SY. Is Cannabis an Effective Treatment for Psoriasis? San Francisco, CA; 2018 Jan [acceso 03/07/2022]. Disponible en: www.healthline.com/health/cannabis-psoriasis
17. Maccarrone M, Di Rienzo M, Battista N, Gasperi V, Guerrieri P, Rossi A, et al. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem. 2003 Sep 5;278(36):33896-903. DOI: https://doi.org/10.1074/jbc.M303994200
18. Wilkinson JD, Williamson EM. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. Journal of dermatological science. 2007 [acceso 03/07/2022];45(2):87-92. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S092318110600315X
19. Oláh A, Markovics A, Szabó-Papp J, Szabó PT, Stott C, Zouboulis CC, Bíró T. Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. Exp. Dermatol. 2016 [acceso 01/07/2022];25:701-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27094344/
20. Ligresti A, De Petrocellis L, Di Marzo V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol. Rev. 2016 [acceso 01/07/2022];96:1593-1659. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27630175/
21. Lipina C, Hundal HS. The endocannabinoid system: 'NO' longer anonymous in the control of nitrergicsignalling? J Mol Cell Biol. 2017 [acceso 01/07/2022];9(2):91-103. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439392/
22. Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, et al. Cannabidiol: state of the art and new challenges for therapeutic applications. PharmacolTher. 2017 [acceso 01/07/2022];175:133-50. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28232276/
23. Maida V, Corban J. Topical medical cannabis: a new treatment for wound pain-three cases of pyodermagangrenosum. J Pain Symptom Manage. 2017;54(5):732-6.
24. Chelliah MP, Zinn Z, Khuu P, Teng JMC. Self-initiated use of topical cannabidiol oil for epidermolysisbullosa. PediatrDermatol. 2018 [acceso 01/07/2022];35(4):e224-e7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29786144/
25. Maida V, Shi RB, Fazzari FGT, Zomparelli L. Topical cannabis-based medicines-A novel paradigm and treatment for non-uremic calciphylaxis leg ulcers: an open label trial. Int. Wound J. 2020 [acceso 01/07/2022];17(5):1508-16. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34013652/
26. Nussbaum SR, Carter MJ, Fife CE, DaVanzo J, Haught R, Nusgart M, et al. An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Non-Healing Wounds. Value in Health. 2018 [acceso 01/07/2022];21:27-32. Disponible en: https://www.sciencedirect.com/sdfe/reader/pii/S1098301517303297/pdf
27. Escandon J, Vivas A, Tang J, Rowland K, Kirsner R. High mortality in patients with chronic wounds. Wound Repair Regen. 2011 [acceso 01/07/2022];19:526-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21649781/
28. Roosterman D, Goerge T, Schneider SW, Bunnett NW, Steinhoff M. Control neuronal de la función cutánea: la piel como órgano neuroinmunoendocrino. Fisiol. Rev. 2006 [acceso 01/07/2022];86:1309-79. Disponible en: https://pubmed.ncbi.nlm.nih.gov/17015491/
29. Mechoulam R, Fride E, Di Marzo V. Endocannabinoides. EUR. J. Pharmacol. 1998 [acceso 01/07/2022];359:1-18. Disponible en: https://pubmed.ncbi.nlm.nih.gov/9831287/
30. Di Marzo V. Endocannabinoides: síntesis y degradación. Rev. Fisiol. Bioquímica Farmacol. 2008 [acceso 02/07/2022];160:1–24. Disponible en: https://pubmed.ncbi.nlm.nih.gov/18481028/
31. Bíró T, Tóth BI, Haskó G, Paus R, Pacher P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci. 2009 Aug;30(8):411-20. DOI: https://doi.org/10.1016/j.tips.2009.05.004
Download
